ClinicalTrials.gg
RecruitingNCT074291362EATUpdated Nov 17, 2026

Plant-based Protein-rich Weight Loss Intervention in 55+ Adults With Obesity

An interventional study of More plant-based protein intake during weight loss in Obesity, sponsored by Amsterdam University of Applied Sciences. Recruiting at 1 site in Netherlands. Open to participants aged 55 Years and older. Per ClinicalTrials.gov, last updated 2026-11-17.

Sponsored by Amsterdam University of Applied Sciences · Not applicable, Interventional, and Treatment

How we know

From the registry’s dates

  • Registered 1 year 3 months after the study started (first participant enrolled Aug 2024, registered Dec 2025).
  • Started Aug 2024; still recruiting 2 years 3 months later.
Updated Nov 17, 2026Primary completion movedStudy completion movedGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
200
Allocation
Randomized
Ages
55 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 248 studies in Obesity with a site in Netherlands — 43 open to participants now, 55 under way, 14 of them phase 3. Obesity · Netherlands.

Planned enrollment
55th of 211
200 · median 58
Started
2024
with 9 others
No phase
128 of 248
17 open now
Primary completion
2027-04
later than 18 of 54 live
Registered
228th of 248
by date

Among the 248 studies in Obesity with a site in Netherlands, this one is the 55th largest by planned enrollment of the 211 interventional ones that give a count, is one of 10 that started in 2024, is one of 128 with no phase, reaches primary completion later than 18 of the 54 other live ones, and was the 228th registered.

Obesity

11,564 studies on the registry are indexed under Obesity; 2,063 are open to participants now.

Browse Obesity studies →

Open to participants now

43 of the 248 studies in Obesity with a site in Netherlands are open now. Recruiting first, the newest first:

38 more — sign in →

All 43 open studies →

A study can be open while its sites in Netherlands have not opened yet or have stopped. Only those recruiting at a site in Netherlands →

Who these studies take

Of the 1,352 Obesity studies recruiting now, 382 (28%) set no upper age limit and 867 (64%) stop at 75 or younger; 169 take children under 18; 491 take healthy volunteers.

This study: 55 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 248 studies in Obesity with a site in Netherlands, or all of them as a file.
02

Study summary

The objective of the 2EAT RCT is to investigate whether a shift towards more plant-based (≥60% with a minimum of 50%) protein intake can be achieved in an energy restricted diet for three and six months in older adults (55+) with obesity.

The 2EAT researchers developed a new dietary counseling plan for six months. This includes four individual consultations, five group meetings and three 24h-recalls. In these six months, participants receive dietary counseling focused on energy restriction (-500 kcal), higher protein intake (aim towards 1.2 g/kg/d, minimum of 0.8 g/kg/d). Participants are randomly allocated either to the more plant-based diet (≥60%) or the more animal-based diet (≥60%). At the start of the intervention, participants are provided with a workbook and recipe book.

Secondary objectives are to assess the effect after three and six months 2EAT dietary treatment on 1) weight loss and 2) skeletal muscle mass. Exploratory objectives are to assess the effect after three and six months 2EAT dietary treatment on 1) physical health outcomes (muscle mass and physical performance), 2) body composition, 3) metabolic blood parameters, 4) vitality and quality of life, 5) nutritional intake, 6) behavioral changes, 7) evaluate the process of the dietary treatment.

03

Conditions studied

  • Obesity

Browse trials for

Keywords

  • Obesity
  • Ageing
04

Who can participate

Ages eligible
55 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Aged 55 or older
  • Are obese: have a of >30 kg/m2 or BMI >27 kg/m2 and waist circumference >88 cm (women) or >102 cm (men)
  • Living independently (not in a health facility)
  • The willingness that the general practitioner will be notified of study participation
  • Written
  • Willingness to comply with the protocol
  • Consent of the study physician

Exclusion criteria

Exclusion Criteria:

  • Inability to understand the Dutch language
  • Cognitive impairment ( \<15)
  • Use of total or partial parenteral nutrition (TPN)
  • Alcohol or drug abuse in the opinion of the investigator
  • Current enrolment in a fixed rehabilitation program or other intervention studies
  • Palliative treatment or a of ≤ 3 months
  • Following a vegetarian or vegan (100% plant-based) diet
  • Bariatric surgery
  • Active medical treatment interfering with this intervention (e.g. weight loss medication as Ozempic, cancer patients receiving systemic and immune therapy)
  • Physical disabled: unable to meet the general daily exercise guideline for adults
  • Planned a holiday during the intervention period and is unable to attend group- or individual sessions for > 3 weeks

The health conditions below will be assessed by the study physician. When a condition interferes the dietary treatment or if the diet worsens the participants health it counts as exclusion criteria:

  • Diagnosed with unstable coronary heart disease (CHD), decompensated heart failure, uncontrolled hypertension or uncontrolled arrhythmias (e.g. heart failure >3)
  • Diagnosed degenerative neurocognitive disorders
  • Diagnosed with renal failure
  • GOLD >3
Terms in these criteria, in plain language(6)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

MMSE and MoCA

Short tests of memory and thinking, each scored out of 30. Lower scores suggest more difficulty; criteria give a range, either to include people with memory problems or to leave them out.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

COPD

Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
200 participants (estimated)

Study arms

  • Experimental
    More plant-based diet

    Participants receive dietary counseling for six months focusing on 1) more plant-based protein (≥60%), 2) higher protein intake (aim 1.2 g/kg/d, minimum 0.8 g/kg/d) and 3) energy restriction (-500 kcal).

    Behavioral: More plant-based protein intake during weight loss

  • Experimental
    More animal-based diet

    Participants receive dietary counseling for six months focusing on 1) more animal-based protein (≥60%), 2) higher protein intake (aim 1.2 g/kg/d, minimum 0.8 g/kg/d) and 3) energy restriction (-500 kcal).

    Behavioral: More plant-based protein intake during weight loss

Interventions

  • BehavioralMore plant-based protein intake during weight loss

    Participants receive dietary counseling for six months focusing on 1) energy restriction (-500 kcal), 2) higher protein intake (aim 1.2 g/kg/d, minimum 0.8 g/kg/d) and according to their assigned diet, either 3) more plant-based protein (≥60%) or more animal-based protein (≥60%).

06

What researchers measure

Primary outcomes

  1. Feasibility of high plant-based protein intake while simultaneously striving for weight loss and increased protein intake

    Three-day food record (plant protein intake as part of total protein intake; g/day)

    Time frame: At baseline (week 0), in week 13 (halfway), in week 26 (end), and optional follow-up (week 52)

Secondary outcomes

  1. Feasibility of a weight loss diet during a more plant-based, higher protein intake

    Three-day food record on energy (kcal/day)

    Time frame: At baseline (week 0), in week 13 (halfway), in week 26 (end), and optional follow-up (week 52)

  2. Feasibility of an increased protein intake during a more plant-based protein, weight loss diet

    Three-day food record on protein intake (g/day)

    Time frame: At baseline (week 0), in week 13 (halfway), in week 26 (end), and optional follow-up (week 52)

  3. Effect of 2EAT dietary treatment on weight loss

    Body weight in kg (calibrated weighing scales)

    Time frame: At baseline (week 0), in week 13 (halfway), in week 26 (end), and optional follow-up (week 52)

  4. Effect of 2EAT dietary treatment on skeletal muscle mass

    Skeletal muscle mass (appendicular lean soft tissue (ALST) in kg) via a DXA-scan

    Time frame: At baseline (week 0), in week 13 (halfway), in week 26 (end), and optional follow-up (week 52)

Other outcomes

  1. Effect of 2EAT dietary treatment on physical performance

    Short Physical Performance Battery (SPPB). Minimum value: 0; Maximum value 12. Score 0-3: severe limitations; score 4-9: intermediate limitations; score 9-12: normal function.

    Time frame: At baseline (week 0), in week 13 (halfway), in week 26 (end), and optional follow-up (week 52)

  2. Effect of 2EAT dietary treatment on walking distance

    400 meter walk test (MWT) in seconds (s)

    Time frame: At baseline (week 0), in week 13 (halfway), in week 26 (end), and optional follow-up (week 52)

  3. Effect of 2EAT dietary treatment on muscle strength

    Hand Grip Strength (kg)

    Time frame: At baseline (week 0), in week 13 (halfway), in week 26 (end), and optional follow-up (week 52)

  4. Effect of 2EAT dietary treatment on fat free mass

    Fat free mass (in kg) via BODPOD air displacement plethysmograph

    Time frame: At baseline (week 0), in week 13 (halfway), in week 26 (end), and optional follow-up (week 52)

  5. Effect of 2EAT dietary treatment on LDL-cholesterol

    Serum LDL-cholesterol (mmol/L)

    Time frame: At baseline (week 0), in week 12 (halfway), in week 26 (end)

  6. Effect of 2EAT dietary treatment on HDL-cholesterol

    Serum HDL-cholesterol (mmol/L)

    Time frame: At baseline (week 0), in week 12 (halfway), in week 26 (end)

  7. Effect of 2EAT dietary treatment on total cholesterol

    Serum total cholesterol mmol/L)

    Time frame: At baseline (week 0), in week 12 (halfway), in week 26 (end)

  8. Effect of 2EAT dietary treatment on triglycerides

    Serum triglycerides (mmol/L)

    Time frame: At baseline (week 0), in week 12 (halfway), in week 26 (end)

  9. Effect of 2EAT dietary treatment on long-term blood glucose concentration

    HbA1c (mmol/mol)

    Time frame: At baseline (week 0), in week 12 (halfway), in week 26 (end)

  10. Effect of 2EAT dietary treatment on insulin resistance

    Homeostasis Model Assessment of Insulin Resistance (HOMA-IR) (values \>2 indicate insulin resistance)

    Time frame: At baseline (week 0), in week 12 (halfway), in week 26 (end)

  11. Effect of 2EAT dietary treatment on inflammation

    High sensitivity CRP (mg/L)

    Time frame: At baseline (week 0), in week 12 (halfway), in week 26 (end)

  12. Effect of 2EAT dietary treatment on vitamin B12 levels

    Serum vitamin B12 (pg/mL)

    Time frame: At baseline (week 0), in week 12 (halfway), in week 26 (end)

  13. Effect of 2EAT dietary treatment on body iron stores

    Serum ferritin (mcg/L)

    Time frame: At baseline (week 0), in week 12 (halfway), in week 26 (end)

  14. Effect of 2EAT dietary treatment on blood haemoglobin concentration

    Blood haemoglobin (mmol/L)

    Time frame: At baseline (week 0), in week 12 (halfway), in week 26 (end)

  15. Effect of 2EAT dietary treatment on vitality

    De Nederlandse vitaliteitsmeter (VITA-16 questionnaire). Minimum value: 0; Maximum value 7. Higher scores indicate more vitality.

    Time frame: At baseline (week 0), in week 13 (halfway), in week 26 (end), and optional follow-up (week 52)

  16. Effect of 2EAT dietary treatment on quality of life

    Short-Form-36 questionnaire (SF-36) Minimum value: 0; Maximum value 100. Higher scores indicate better health-related quality of life. A score of 0 indicates very poor health-related quality of life, whereas a score of 100 indicates a very good health-related quality of life.

    Time frame: At baseline (week 0), in week 13 (halfway), in week 26 (end), and optional follow-up (week 52)

  17. Effect of 2EAT dietary treatment on carbohydrate intake

    Three-day food record on carbohydrate (g/day)

    Time frame: At baseline (week 0), in week 13 (halfway), in week 26 (end), and optional follow-up (week 52)

  18. Effect of 2EAT dietary treatment on fat intake

    Three-day food record on fat (g/day)

    Time frame: At baseline (week 0), in week 13 (halfway), in week 26 (end), and optional follow-up (week 52)

  19. Effect of 2EAT dietary treatment on saturated fat intake

    Three-day food record on saturated fat (g/day)

    Time frame: At baseline (week 0), in week 13 (halfway), in week 26 (end), and optional follow-up (week 52)

  20. Effect of 2EAT dietary treatment on fiber intake

    Three-day food record on fiber (g/day)

    Time frame: At baseline (week 0), in week 13 (halfway), in week 26 (end), and optional follow-up (week 52)

  21. Effect of 2EAT dietary treatment on calcium intake

    Three-day food record on calcium (mg/day)

    Time frame: At baseline (week 0), in week 13 (halfway), in week 26 (end), and optional follow-up (week 52)

  22. Effect of 2EAT dietary treatment on iron intake

    Three-day food record on iron (mg/day)

    Time frame: At baseline (week 0), in week 13 (halfway), in week 26 (end), and optional follow-up (week 52)

  23. Effect of 2EAT dietary treatment on zinc intake

    Three-day food record on zinc (mg/day)

    Time frame: At baseline (week 0), in week 13 (halfway), in week 26 (end), and optional follow-up (week 52)

  24. Effect of 2EAT dietary treatment on magnesium intake

    Three-day food record on magnesium (mg/day)

    Time frame: At baseline (week 0), in week 13 (halfway), in week 26 (end), and optional follow-up (week 52)

  25. Effect of 2EAT dietary treatment on selenium intake

    Three-day food record on selenium (mcg/day)

    Time frame: At baseline (week 0), in week 13 (halfway), in week 26 (end), and optional follow-up (week 52)

  26. Effect of 2EAT dietary treatment on vitamin B1 intake

    Three-day food record on vitamin B1 (mg/day)

    Time frame: At baseline (week 0), in week 13 (halfway), in week 26 (end), and optional follow-up (week 52)

  27. Effect of 2EAT dietary treatment on vitamin B2 intake

    Three-day food record on vitamin B2 (mg/day)

    Time frame: At baseline (week 0), in week 13 (halfway), in week 26 (end), and optional follow-up (week 52)

  28. Effect of 2EAT dietary treatment on vitamin B6 intake

    Three-day food record on vitamin B6 (mcg/day)

    Time frame: At baseline (week 0), in week 13 (halfway), in week 26 (end), and optional follow-up (week 52)

  29. Effect of 2EAT dietary treatment on folic acid intake

    Three-day food record on folic acid (mcg/day)

    Time frame: At baseline (week 0), in week 13 (halfway), in week 26 (end), and optional follow-up (week 52)

  30. Effect of 2EAT dietary treatment on vitamin B12 intake

    Three-day food record on vitamin B12 (mcg/day)

    Time frame: At baseline (week 0), in week 13 (halfway), in week 26 (end), and optional follow-up (week 52)

  31. Effect of 2EAT dietary treatment on vitamin C intake

    Three-day food record on vitamin C (mg/day)

    Time frame: At baseline (week 0), in week 13 (halfway), in week 26 (end), and optional follow-up (week 52)

  32. Effect of 2EAT dietary treatment on vitamin D intake

    Three-day food record on vitamin D (mcg/day)

    Time frame: At baseline (week 0), in week 13 (halfway), in week 26 (end), and optional follow-up (week 52)

  33. Effect of 2EAT dietary treatment on vitamin E intake

    Three-day food record on vitamin E (mg/day)

    Time frame: At baseline (week 0), in week 13 (halfway), in week 26 (end), and optional follow-up (week 52)

  34. Effect of 2EAT dietary treatment on behavior, dimension "diffuse emotions"

    Nederlandse Vragenlijst Eetgedrag (NVE) questionnaire on dimension "diffuse emotions". Sum questions 3, 8, 10, 28 and divide by 4. Minimal score: 0; maximal score: 5. A score of 5 means the individual has a lot of diffuse emotions, a score of 0 means no diffuse emotions.

    Time frame: At baseline (week 0), in week 13 (halfway), in week 26 (end), and optional follow-up (week 52)

  35. Effect of 2EAT dietary treatment on behavior, dimension "clearly described emotions"

    Nederlandse Vragenlijst Eetgedrag (NVE) questionnaire on dimension "clearly described emotions". Sum questions 1, 5, 13, 16, 20, 23, 25, 30, 32 and divide by 9. Minimal score: 0; maximal score: 5. A score of 5 means the individual has clearly described emotions, a score of 0 means no clearly described emotions.

    Time frame: At baseline (week 0), in week 13 (halfway), in week 26 (end), and optional follow-up (week 52)

  36. Effect of 2EAT dietary treatment on behavior, dimension "emotional eating"

    Nederlandse Vragenlijst Eetgedrag (NVE) questionnaire dimension "emotional eating". Sum questions 1, 3, 5, 8, 10, 13, 16, 20, 23, 25, 28, 30, 32 and divide by 13. Minimal score: 0; maximal score: 5. A score of 5 means the individual is a very emotional eater, a score of 0 means no emotional eating.

    Time frame: At baseline (week 0), in week 13 (halfway), in week 26 (end), and optional follow-up (week 52)

  37. Effect of 2EAT dietary treatment on behavior, dimension "external eating"

    Nederlandse Vragenlijst Eetgedrag (NVE) questionnaire dimension "external eating". Sum questions 2, 6, 9, 12, 15, 18, 21, 24, 27, 33 and divide by 10. Minimal score: 0; maximal score: 5. A score of 5 means the individual is a very external eater, a score of 0 means no external eating.

    Time frame: At baseline (week 0), in week 13 (halfway), in week 26 (end), and optional follow-up (week 52)

  38. Effect of 2EAT dietary treatment on behavior, dimension "diet-oriented eating"

    Nederlandse Vragenlijst Eetgedrag (NVE) questionnaire dimension "diet-oriented eating". Sum questions 4, 7, 11, 14, 17, 19, 22, 26, 29, 31 and divide by 10. Minimal score: 0; maximal score: 5. A score of 5 means the individual is a very diet-oriented eater, a score of 0 means no diet-oriented eating.

    Time frame: At baseline (week 0), in week 13 (halfway), in week 26 (end), and optional follow-up (week 52)

  39. Process evaluation of the 2EAT dietary treatment

    Paper-based questionnaire with open questions

    Time frame: At week 26 (end)

  40. End evaluation of the 2EAT dietary treatment

    Paper-based questionnaire with open questions

    Time frame: Optional follow-up (week 52)

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: Undecided — Participants have agreed or disagreed to share data later. At this moment it is still undecided whether we will share data.

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Aug 2024 (actual). Primary completion is estimated for Apr 2027, 32 months after the start.

Of 3,697 non-industry interventional studies with no phase under Obesity, half reached primary completion within 23 months of starting (the median), counting those still running; a quarter within 10 and three quarters within 43. This study's planned 32 months is above that.

Counting every sponsor, half of 3,861 studies reached it within 22 months; a quarter within 9 and three quarters within 42.

Primary completion moved once since we started tracking on Sep 25, 2026: Oct 2026 → Apr 2027, on Nov 17, 2026.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Dec 8, 2025
First posted
Feb 24, 2026
StartActual
Aug 13, 2024
Primary completionEst.
Apr 30, 2027was Oct 2026
CompletionEst.
Apr 30, 2027
Last update
Nov 17, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Primary completion
Oct 1, 2026→Apr 30, 2027
Nov 17, 2026
Study completion
Apr 1, 2027→Apr 30, 2027
Nov 17, 2026
Show all 1 update
  1. Nov 17, 2026
    Primary completion Oct 1, 2026→Apr 30, 2027
    Study completion Apr 1, 2027→Apr 30, 2027
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07429136
Lead sponsor
Amsterdam University of Applied Sciences
Responsible party
Sponsor
First posted
Feb 24, 2026
Start date
Aug 13, 2024
Primary completion
Apr 30, 2027 (estimated)
Completion
Apr 30, 2027 (estimated)
Last update
Nov 17, 2026

Study contacts

Susanne Wildemast
Contact
s.wildemast@hva.nl
+31623492734
Sjors Verlaan
Contact
s.verlaan@hva.nl
+31657442955
Peter Weijs
principal investigator · Amsterdam University of Applied Sciences

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion